Results 101 to 110 of about 2,530 (165)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration. [PDF]

PURPOSE: To report our real-world experience using intravitreal faricimab, a novel anti-vascular endothelial growth factor (anti-VEGF) therapy, in eyes with neovascular age-related macular degeneration (nAMD) previously treated with other anti-VEGF ...
Emami-Naeini, Parisa, Hang, Abraham, Moshiri, Ala, Moussa, Kareem, Ngo, Taylor, Park, Susanna, Virk, Jaipreet   +6 more
core   +1 more source

Exploring the Spectrum of VEGF Inhibitors? Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice [PDF]

The use of Vascular Endothelial Growth Factor inhibitors (VEGFi) has become prevalent in the field of medicine, given the high incidence of various pathological conditions necessitating VEGF inhibition within the general population.
Berretta, M., Capuozzo, M., Correra, M., Di Mauro, A., Di Mauro, G., Granata, V., Gualillo, O., Maiolino, P., Nasti, G., Ottaiano, A., Sabbatino, F., Santorsola, M., Vanni, G.   +12 more
core   +1 more source

Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration – A systematic review and meta-analysis [PDF]

Age-related macular degeneration (AMD) is one of the leading causes of blindness in the world and anti-vascular endothelial growth factor (VEGF) injections have been the standard of care for the wet/neovascular variant since 2004.
Hoven, Erlend, Lagali, Neil Satish, Michelet, John-Thomas Edward, Vettore, Mario Vianna   +3 more
core   +1 more source

Real-world evidence for brolucizumab efficacy in age-related macular degeneration and central serous chorioretinopathy patients

Heliyon
Real-world studies concerning different populations are valuable and bring new information regarding different regimens of Brolucizumab injections and their adverse reactions. The present study investigates the efficacy of a pro-re-nata regimen (PRN) for
Samoila Lacramioara, Samoila Ovidiu, Clichici Simona   +2 more
doaj   +1 more source

Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry

Ophthalmology and Therapy
Introduction To assess real-world safety outcomes for adults with neovascular age-related macular degeneration (nAMD) treated with brolucizumab from the US-based IRIS® (Intelligent Research in Sight) Registry.
Marco A. Zarbin, Mathew W. MacCumber, Helene Karcher, Eser Adiguzel, Andrew Mayhook, Andrew LaPrise, Ver L. Bilano, Franklin Igwe, Michael S. Ip, Charles C. Wykoff   +9 more
doaj   +1 more source

The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration

Journal of Ophthalmology
Aim. To evaluate the short-term efficacy of using a monoclonal antibody fragment (Brolucizumab) for treating neovascular age-related macular degeneration, depending on the morphometric parameters of the retina. Methods: This study included 48 patients
A. F. Yusupov, M. Kh. Karimova, S. A. Djamalova, D. K. Makhkamova, S. I. Abdullaeva, M. A. Zakirkhodjaeva, Khodjaeva Zilola, D. A. Rakhimova   +7 more
doaj   +1 more source

Preclinical challenges for developing long acting intravitreal medicines [PDF]

, 2020
The majority of blinding conditions arise due to chronic pathologies in the retina. During the last two decades, antibody-based medicines administered by intravitreal injection directly into the back of the eye have revolutionised the treatment of ...
Awwad, S, Brocchini, S, Henein, C, Ibeanu, N, Khaw, PT   +4 more
core  

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration

International Medical Case Reports Journal, 2020
Jaycob Avaylon,1 Sol Lee,2 Ron P Gallemore2 1California Northstate University, College of Medicine, Elk Grove, CA, USA; 2Retina Macula Institute, Torrance, CA, USACorrespondence: Ron P GallemoreRetina Macula Institute, 4201 Torrance Blvd., Ste 220 ...
Avaylon J, Lee S, Gallemore RP
doaj  

Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data [PDF]

, 2022
Eandi, Chiara M
core   +1 more source

Comparative Analysis of Intravitreal Dexamethasone Implant (Ozurdex) and Brolucizumab Injection in the Treatment of Diabetic Macular Edema with Hyperreflective Intraretinal Dots: A Retrospective Study

Clinical Ophthalmology
Somnath Chakraborty,1 Jay Umed Sheth2 1Department of Vitreoretinal Services, Retina Institute of Bengal, Siliguri, West Bengal, India; 2Department of Vitreoretinal Services, Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, IndiaCorrespondence ...
Chakraborty S, Sheth JU
doaj